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Background: The discovery of sodium-glucose co-transporter 2 (SGLT2) inhibitors, with a novel mechanism independent
of insulin secretion or sensitization, bring about a new therapeutic approach to the management of type 2 diabetes
mellitus. The aim of this meta-analysis was to evaluate the safety and efficacy of SGLT2 inhibitors at different doses in
randomized double blind clinical trials.
Methods: This meta-analysis was conducted by including randomized double-blind controlled trials of SGLT2 inhibitors
in patients with type 2 diabetes irrespective of their antidiabetic drug exposure history but with an inadequate
glycemic control. All the effect sizes were computed using the random effects model. Standardized mean differences
(SMDs) and odds ratios (OR) were computed for continuous and dichotomous variables, respectively. Additional
analyses like sensitivity analysis, subgroup analysis and meta-regression were also performed.
Results: The pooled analyses demonstrated a significant reduction in mean changes in Hemoglobin A1c (HbA1c)
(SMD = −0.78%, 95% CI, -0.87 to −0.69), fasting plasma glucose (FPG) (SMD = −0.70 mg/dl, 95% CI, -0.79 to −0.61), body
weight (overall SMD = −0.59 kg, 95% CI, -0.65 to −0.52) and blood pressure from baseline with SGLT2 inhibitors based
therapy. Consistently a significant number of patients treated with SGLT2 inhibitors achieved HbA1c < 7% (OR = 2.09,
95% CI, 1.77 to 2.46). SGLT2 inhibitors based therapy was associated with adverse events like genital and urinary tract
infections.
Conclusion: All studied doses of SGLT2 inhibitors, either as monotherapy or in combination with other antidiabetic
agents, consistently improved glycemic control in patients with type 2 diabetes. However, a small percentage of
patients suffer from genital and urinary tract infections.
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The persistent hyperglycemia in patients with type 2 dia-
betes mellitus is strongly associated with microvascular and
macrovascular complications [1]. Chronic hyperglycemia is
postulated to contribute to the continuous loss of pancre-
atic β-cells and the impairment of insulin secretion [2].
Microvascular complications like diabetic retinopathy, ne-
phropathy, and neuropathy are major causes of new cases* Correspondence: asresb@hu.edu.et
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distribution, and reproduction in any mediumof blindness and renal insufficiency [3]. Moreover, in type 2
diabetes macrovascular complications, including coronary
heart disease and stroke, are major causes of morbidity and
mortality [4]. According to a prospective study, in patients
with type 2 diabetes, a 1% increase in HbA1c was asso-
ciated with 20% to 30% increase in mortality or cardiovas-
cular events [5].
Intensive glycemic control in patients with type 2 can
delay the onset and progression of the early stages of dia-
betic microvascular complications [6]. In the UKPDS, a
reduction in mean HbA1c was associated with reductions
in both microvascular and macrovascular complicationsentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and heart failure was relatively low [1]. Furthermore a
meta-analysis of randomized controlled trials reported
that an intensive glycemic control resulted in no signifi-
cant effect on events of stroke or all-cause mortality [7].
As a result, researchers recommend a multidisciplinary
approach to the management of the cardiovascular risk
factors in patients with type 2 diabetes [8].
Currently many antidiabetic agents are available with a
variety of chemical groups and site of actions. Most of
these agents act by either improving the insulin sensitivity
or by enhancing insulin secretion. Nevertheless, as the
pancreatic β-cells function continues to decline, failure of
therapy to achieve adequate glycemic control is inevitable.
The cumulative incidence of monotherapy failure was
15% with rosiglitazone, 21% with metformin, and 34%
with glyburide after 5 years of therapy [9]. On the other
hand, agents like insulin, sulphonylureas, and thiazolidine-
diones are associated with significant safety concerns such
as weight gain and hypoglycemic events [9,10].
The discovery of SGLT2 inhibitors, with novel mech-
anism independent of insulin secretion or sensitization,
may possibly expand the armamentarium in the battle
against type 2 diabetes mellitus. SGLT2 plays an import-
ant role in the kidneys and is responsible for most renal
glucose re-absorption in the proximal convoluted tubule
[11]. Currently there are a number of SGLT2 inhibitors
that are under development or in clinical trials [12].
Prior meta-analyses had established the safety and effi-
cacy of SGLT2 inhibitors as a group [13,14]. However,
recently published randomized clinical trials reported
more frequent adverse events with SGLT2 inhibitors and
no significant difference in the proportion of patients
achieving HbA1c levels <7.0% as compared to placebo
treated [15,16]. Thus, the primary aim of this meta-
analysis is to determine the safety and efficacy of SGLT2
inhibitors alone or in combination with other anti-
diabetic drugs relative to placebo or placebo with other
anti-diabetic drugs by including both previously and re-
cently published randomized double blind clinical trials.
Methods
Search strategy
Electronic based literature search was conducted in the
databases of MEDLINE, HINARI, EBASE and The
Cochrane Library by both authors (AB and AB). The lit-
erature search was further strengthened by searching
relevant articles from the reference list of retrieved arti-
cles. During searching the following search terms were
alternatively combined using the Boolean logic (AND,
OR and NOT): sodium glucose co-transport (SGLT) in-
hibitors, dapagliflozin, canagliflozin, ipragliflozin, empa-
gliflozin, sergliflozin etabonate, remogliflozin etabonate,
tofogliflozin and type 2 diabetes.Inclusion criteria and study selection
The predetermined study inclusion criteria were: (1) ran-
domized double-blind controlled trials of SGLT2 inhibi-
tors in patients with type 2 diabetes mellitus; (2) studies
which recruited patients with type 2 diabetes irrespective
of their antidiabetic drug exposure history (naïve or drug
experienced) but with an inadequate glycemic control
(HbA1c ≥7.0); (3) studies written in English and (4)
studies with a minimal duration of therapy for 12 weeks.
The study selection of the retrieved literature was con-
ducted in two steps: First, all the retrieved literature ti-
tles and abstracts were reviewed and then grouped
either under “eligible for full document review” or “ineli-
gible for full document review”. Second, all literatures
that were grouped under “eligible for full document re-
view” were reviewed in detail and then grouped as “eli-
gible for the meta-analysis” or “ineligible for the meta-
analysis”.
Data extraction and quality assessment
Data extraction from the selected studies was conducted
by both authors independently with the same data ex-
traction template. Standard Excel spreadsheets were
used for the data extraction. The following information
was abstracted from the included studies: name of the
first author, year of publication, sites of the study, the
study design, duration of therapy, antidiabetic drugs
used by the patients before they were recruited in the
studies, antidiabetic drugs used in combination with
SGLT2 inhibitors, dose, change in HbA1C(%) from base-
line, number of patients with HbA1c < 7.0%, change in
FPG, change in body weight, change in blood pressure,
number of patients with adverse events, And number of
patients who discontinued medication due to adverse
events, experienced serious adverse events, experienced
hypoglycemia, experienced urinary tract infection, and
experienced genital tract infection.
Risk of bias in every of the included studies was assessed
by the Cochrane risk of bias assessment tool. The pre-
defined key domains were: random sequence gener-
ation, allocation concealment, blinding of participants
and personnel, blinding of outcome assessment, incom-
plete outcome data, selective reporting and other bias.
Based on the included articles, each domain was judged
as “low risk of bias” or “unclear risk of bias” or “high
risk of bias”.
Data synthesis and statistical analysis
Before the pooled analyses were conducted, some stat-
istical transformations and unit conversions were per-
formed. In case of continuous variables, where the
standard deviation (SD) was not reported in the in-
cluded studies, we computed the SD from standard er-
rors (SE), 95% confidence intervals (CI) or P-values.
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converted to mg/dl using an online converter [17].
All effect sizes in this meta-analysis were computed
using the random effects model. SMDs and the 95% CIs
were computed for the changes in HbA1C (%), FPG, body
weight, and blood pressure from baseline using the inverse
variance method (IV). For dichotomous variables (adverse
events, discontinuation of medication due to adverse
events, serious adverse events, hypoglycemic events, urin-
ary tract infection, and genital tract infection) ORs and
95% CIs were computed with Mantel-Haenszel method
(M-H). When the 95% CI does not include zero for the
SMDs and one for ORs, it was considered as statistically
significant. Sensitivity analysis was performed by removing
a study with a specific dose from the analysis at a time to
evaluate the stability of the pooled values.
The consistency of the included studies was evaluated by
the heterogeneity test (I2 statistics); when the value of I2 is
greater than or equal to 50%, the included studies were
considered as statistically inconsistent. To identify the pos-
sible sources of heterogeneity subgroup analysis and meta-
regression were conducted. Publication bias was assessed
by funnel plots and by funnel plot asymmetry test (Egger’s
test). All the statistical analyses were performed with
OpenMetaAnalyst software and Review Manager (Rev-
Man) Version 5.1 software. We reported the meta-analysis
by following the PRISMA checklist.
Results
Using the Google scholar search engine about 6,390 litera-
tures on SGLT2 inhibitors were identified. One hundredWith the Google scholar search engine 6,390
literatures were identified
104 articles were retrieved further screening
26 articles were accepted for full document rev
17 (11 on dapagliflozin, 3 on canagliflozin, 2 on
Ipragliflozin and 1 on empagliflozin) articles me
predetermined inclusion criteria
Figure 1 Study selection flow diagram.and four articles were retrieved. After reviewing the ab-
stracts of all the retrieved articles 26 articles were selected
for full document review. Then, following the full docu-
ment review of the 26 articles, 17 fulfilled the predeter-
mined inclusion criteria. Eleven of studies were on
dapagliflozin [15,18-27], 3 on canagliflozin [16,28,29], 2 on
ipragliflozin [30,31], and the remaining one was on empa-
gliflozin [32] (Figure 1). A total of 4,811 patients with type
2 diabetes received one of the SGLT2 inhibitors alone
(2,686) or in combination with other antidiabetic drugs
(2,125) and 1,921 received placebo (887) or placebo with
other antidiabetic drugs (1,034) (Table 1). The risk of bias
assessment in the included individual studies did not dem-
onstrate the presence of bias in randomization, blinding
or reporting. Similarly, funnel plot did not also show the
existence of publication bias.
As presented in Figure 2, the pooled analysis of the
mean change in HbA1c from baseline established a sig-
nificant reduction in patients who were treated with
SGLT2 inhibitors than placebo treated patients (overall
SMD = −0.78; 95%CI, -0.86 to −0.69). All the SGLT2
inhibitors included in the meta-analysis, canagliflozin
(subtotal SMD= −0.97; 95%CI, -1.25 to −0.69) dapagliflozin
(subtotal SMD= −0.73; 95%CI, -0.82 to −0.64), ipragliflozin
subtotal SMD= −0.68; 95%CI, -0.861 to −0.490) and empa-
gliflozin subtotal SMD= −0.78; 95%CI, -0.967 to −0.599),
demonstrated the significant reduction in HbA1c. The re-
duction in HbA1c appears more prominent in canagliflozin
treated patients. However, heterogeneity testing revealed
the presence of a considerable heterogeneity among
the studies on canagliflozin (I2 = 90%) and a moderateAfter screening the titles,
6,286 literatures were
excluded
78 articles were excluded after
reviewing the abstracts
iew                  After a full document
review 9 articles were
excluded
t the





Group 1 (n) Group 2 (n) Group 3 (n) Group 4 (n) Group 5 (n) Group 6 (n)
Rosenstock J et al S1 [28] 2012 12 Metformin Metformin PBO (65) CANA 50 mg QD (64) CANA 100 mg QD (64) CANA 200 mg QD (65) CANA 300 mg QD (64) CANA 300 mg BID (64)
Yale JF et al [29] 2013 26 N/R N/R PBO (90) CANA 100 mg QD (90) CANA 300 mg QD (89)
Stenlof K et al [16] 2013 26 Diet and exercise - PBO (192) CANA 100 mg QD (195) CANA 300 mg QD (197)
Ferrannini E et al S1 [32] 2013 12 PBO (82) EMPA 5 mg QD (81) EMPA 10 mg QD (81) EMPA 25 mg QD (82)
Fonseca VA et al [31] 2012 12 N/R - PBO (69) IPRA 12.5 mg QD (70) IPRA 50 mg QD (67) IPRA150 mg QD (68) IPRA 300 mg QD (68)
Wilding JPH et al S1 [30] 2013 12 Metformin - PBO (66) IPRA 12.5 mg QD (69) IPRA 50 mg QD (68) IPRA 150 mg QD (67) IPRA 300 mg QD (72)
Wilding JPH et al S2 [18] 2009 12 Insulin PBO (19) DAPA 10 mg QD (23) DAPA 20 mg QD (23)
Bailey CJ et al S1 [19] 2012 24 Naïve - PBO (68) DAPA 1 mg QD (72) DAPA 2.5 mg QD (72) DAPA 5.0 mg QD (66)
Ferrannini E et al S2 [20] 2010 24 Naïve - PBO (75) DAPA 2.5 mg QD (65) DAPA 5.0 mg QD (64) DAPA 10 mg QD (70)
Henry RR et al [21] 2012 24 Naïve Metformin PBO 1 (201) DAPA 5 mg QD (194) DAPA 10 mg QD (211) PBO 2 (208)
Strojek K et al [22] 2011 24 Glimepiride Glimepiride PBO (145) DAPA 2.5 mg QD (154) DAPA 5 mg QD (142) DAPA 10 mg QD (151)
Bailey CJ et al S2 [23] 2010 24 Metformin - PBO (137) DAPA 2·5 mg QD (137) DAPA 5 mg QD (137) DAPA 10 mg QD (135)
Bolinder J et al [24] 2012 24 N/R Metformin PBO (91) DAPA 10 mg QD (88)
Rosenstock J et al S2 [25] 2012 24 Pioglitazone Pioglitazone PBO (139) DAPA 5 mg QD (141) DAPA 10 mg QD (140)
Kaku K et al [5] 2013 12 Naïve - PBO (54) DAPA 1 mg QD (59) DAPA 2.5 mg QD (56) DAPA 5 mg QD (58) DAPA 10 mg QD (52)
Wilding JPH et al S3 [26] 2012 24 Insulin Insulin PBO (166) DAPA 2.5 mg QD (179) DAPA 5 mg QD (185) DAPA 10 mg QD (173)
List JF et al [27] 2009 12 Naïve - PBO (54) DAPA 2.5 mg QD (59) DAPA 5 mg QD (58) DAPA 10 mg QD (47) DAPA 20 mg QD (59) DAPA 50 mg QD (56)




















Figure 2 Standardize mean difference of the change in HbA1c from baseline.
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57%) and ipragliflozin (I2 = 56%).
Subgroup analysis based on the doses of SGLT2 in-
hibitors and the type of regimen (SGLT2 inhibitors
monotherapy vs SGLT2 inhibitors in combination with
other antidiabetic drugs) and meta-regression using dur-
ation of therapy and the doses of SGLT2 inhibitors as a
covariates did not show a significant difference in HbA1c
change from baseline. On the other hand sensitivity ana-
lysis confirmed the stability of the overall SMD when any
of the studies with a specific dose removed from the ana-
lysis. The overall SMD ranged within −0.75 to −0.79%.
In support of the above analysis, the odds of SGLT2
inhibitors treated patients who achieved HbA1c < 7.0%
were more than two folds of placebo treated groups
(overall OR = 2.09; 95% CI, 1.77 to 2.46). Similarly, the
mean FPG levels (overall SMD = −0.70 mg/mL, 95% CI,
-0.79 to −0.61) and mean body weight (overall SMD =
−0.59 kg; 95% CI, −0.66 to −0.52) of patients who were
treated with SGLT2 inhibitors were significantly de-
creased from baseline compared to placebo treated pa-
tients (Figure 3). Furthermore, treatment with SGLT2
inhibitors was significantly associated with a reduction
in both systolic (overall SMD = −0.27 (mmHg; 95% CI,
-0.34 to −0.20) and diastolic (overall SMD = −0.24, 95%
CI, -0.30 to −0.17) blood pressure from baseline. Most
of the individual studies did not show the significant as-
sociation of SGLT2 inhibitors with an increase in HDL
cholesterol level from baseline. However, the overall
SMD demonstrated a significant increase in HDL chol-
esterol level in patients who were treated with SGLT2
inhibitors (overall SMD = 0.21 mg/dl; 95% CI, 0.09 to
0.33). The change in the level of LDL cholesterol from
baseline in SGLT2 inhibitors treated groups was not dif-
ferent from placebo treated groups (overall SMD =
0.07 mg/l; 95% CI, -0.01 to 0.14).
Even though the SGLT2 inhibitors with all doses did
not show association with adverse events, the overall OR
revealed the significant association of SGLT2 inhibitors
with adverse events (overall OR = 1.18; 95% CI, 1.08 to
1.29) (Figure 4). The subtotal ORs in the subgroups of
canagliflozin (subtotal OR = 1.31; 95% CI, 1.08 to 1.59)
and dapagliflozin (subtotal OR = 1.17; 95% CI, 1.05 to
1.31) showed significant association with adverse events.
Whereas the subtotal ORs in the subgroups of ipragliflo-
zin was not statistically significant (OR = 0.95; 95% CI,
0.677 to 1.325). Dapagliflozin (subtotal OR = 3.07; 95%
CI, 2.32 to 4.05) and canagliflozin (subtotal OR = 3.42;
95% CI, 1.86 to 6.28) were associated with genital tract
infections. Dapagliflozin was also associated with urinary
tract infection (subtotal OR = 1.32; 95% CI, 1.06 to 1.63).
Nevertheless the number of patients who were treated
with SGLT2 inhibitors and experienced serious adverse
events was not different from placebo treated groups(overall OR = 0.83; 95% CI, 0.65 to 1.05). Similarly the
number of patients who experienced hypoglycemic
events during the study periods was not different from
placebo treated groups (overall OR = 1.16; 95% CI, 0.94
to 1.43). As presented in Figure 5, The odds of discon-
tinuation of medication due to adverse events in the
SGLT2 inhibitors treated patients was not significantly
different from placebo treated patients (overall OR =
1.05; 95% CI, 0.81 to 1.36).
Discussion
In agreement with prior meta-analyses [13,14] this meta-
analysis demonstrated the significant improvement of
glycemic control in patients with type 2 diabetes treated
with SGLT2 inhibitors. Patients treated with SGLT2 in-
hibitors either as monotherapy or in combination with
other antidiabetic agents significantly decreased HbA1c
and FPG from baseline at all doses studied as compared
to patients treated with placebo or placebo with other
antidiabetic agents. A significantly large number of pa-
tients treated with SGLT2 inhibitors achieved HbA1c <
7% at the end of the study period of the included studies.
The reduction of HbA1c from baseline with SGLT2 in-
hibitors may reflect the long term mean glycemic con-
trol for the previous 2 to 3 months; while, FPG indicates
the glycemic control on the day of the visit [33,34].
On top of this, the meta-regression and subgroup ana-
lysis did not demonstrate a significant change in the effi-
cacy of SGLT2 inhibitors depending on the duration of
therapy and the doses SGLT2 inhibitors studied. Accord-
ingly, the glycemic control with SGLT2 inhibitors does
not seem to decline when the duration of therapy gets
longer. On the other hand, the increase in doses of
SGLT2 inhibitors was not accompanied by an increase
in the efficacy of SGLT2 inhibitors. A phase 3 long-term
extension dapagliflozin study (102 weeks), reported the
sustained reductions in HbA1c and FPG level [35]. How-
ever, the finding of the meta-regression should not be
taken as a confirmation of the long term efficacy and
safety of SGLT2 inhibitors at all doses. The included
studies in the meta-regression reported the change in
HbA1c and FPG level after a duration of therapy not
more than 26-weeks (Table 1).
Treatment with SGLT2 inhibitors was associated with
a significant reduction in body weight, systolic and dia-
stolic blood pressure. Therapy with SGLT2 inhibitors
was associated with a rise in HDL cholesterol level with-
out a significant change in LDL cholesterol level. Pro-
vided that most of the antidiabetic agents are associated
with weight gain [9,10] and the vast majority of patients
with type 2 diabetes are overweight or obese [36], the
introduction of SGLT2 inhibitors with an insulin inde-
pendent mechanism could have a pivotal role in the
management of type 2 diabetes. The drop in blood
Figure 3 Standardize mean difference of the change in body weight from baseline.
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Figure 4 Mantel-Haenszel odds ratio of patients who experienced any adverse events.
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Figure 5 Mantel-Haenszel odds ratio of patients who discontinued the treatment due to adverse events.
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inhibitor therapy could even make SGLT2 inhibitors more
promising. This is because; in patients with type 2 diabetes
the major cause of morbidity and mortality is attributed tocardiovascular diseases [4,37]. But SGLT2 inhibitors long
term effects on cardiovascular outcomes is uncertain.
Moreover, in this study, the meta-analyses of change in
blood pressure and cholesterol levels were not controlled
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was strongly associated with a drop in blood pressure and
a change in cholesterol levels [38,39], the changes in blood
pressure and cholesterol levels in SGLT2 inhibitors treated
groups could be mediated by the weight changes.
This meta-analysis has shown a statistically significant
association of SGLT2 inhibitors based therapy with ad-
verse events. The number of patients experiencing geni-
tal or urinary tract infections was significantly higher in
SGLT2 inhibitors treated groups than placebo treated
groups. Both genital and urinary tract infections were
more common among females than males [40]. How-
ever, the proportions of patients with severe adverse
events, hypoglycemic events and discontinuation of
medication because of adverse events in SGLT2 inhibi-
tors treated groups were not different from placebo
treated groups. Similarly, previous meta-analyses reported
an increased risk of urinary and genital tract infections with
dapagliflozin without a significant increase in hypoglycemic
events [13,14]. Moreover, a study of women with type 2 dia-
betes has established the significant association of canagli-
flozin therapy with vulvovaginal candidiasis [41].
As limitations, firstly heterogeneity testing has revealed
the presence of significant inconsistency among the in-
cluded studies. But, the uncertainty of the results from this
meta-analysis did not appear increased. This is because;
sensitivity analysis by removing any of the study with a spe-
cific dose from the analysis confirmed the stability of the
overall values. The possible explanation for the significant
heterogeneity could be: the variation in the patients’ antidi-
abetic agents experience, the variation in the SGLT2 inhibi-
tors regimens, and the difference in baseline demographic
and clinical characteristics of the patients recruited.
Secondly, a pooled data from phase 2b and 3 clinical tri-
als has shown an increased incidence of cancer and hep-
atotoxicity with dapagliflozin [42]. This meta-analysis did
not have any evidence to rule out or to share these con-
cerns. That is, further analyses were not conducted to de-
termine the association of SGLT2 inhibitors with rare
adverse events like cancer development and hepatotox-
icity. Meta-analysis of rare adverse events, using studies
that were not primarily designed to test adverse events,
can yield misleading information [43]. Thirdly, since all
the included studies were sponsored by pharmaceutical
companies, the findings of studies could be biased by busi-
ness interests. Lastly, the number of studies on canagliflo-
zin, ipragliflozin and empagliflozin that were included in
this meta-analysis is very small. Thus, the pooled values of
this meta-analysis may not reveal the clinical effect.
Conclusion
In conclusion, in patients with type 2 diabetes, all stud-
ied doses of SGLT2 inhibitors either as monotherapy or
in combination with other antidiabetic agents improvedglycemic control consistently. Furthermore SGLT2 in-
hibitors were associated with a significant reduction in
body weight and blood pressure. However, a small per-
centage of patients suffer from genital and urinary tract
infections. Yet, SGLT2 inhibitors appear to be safe as the
number of hypoglycemic events and the number of pa-
tients who discontinued therapy were similar between
SGLT2 inhibitor treated groups from placebo treated pa-
tients. Finally, further investigations with long term dur-
ation of therapy are needed to establish the safety and
efficacy of SGLT2 inhibitors.
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